1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Comments due May 29, 2026 per the stored deadline. The Federal Register page was inaccessible to automated scraping (redirected to unblock page) but the document metadata confirms its existence with document number 2026-08281 published 2026-04-29.
AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information is sponsored by Food and Drug Administration (FDA). The Food and Drug Administration (FDA) is issuing this request for information to solicit input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trial…
Get alerted about grants like this
Save a search for “Food and Drug Administration (FDA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Federal Register :: Request Access Due to aggressive automated scraping of FederalRegister. gov and eCFR. gov, programmatic access to these sites is limited to access to our extensive developer APIs.
Please visit documentation to learn more about how to access the API. Your request has been flagged as potentially automated. If you are human user receiving this message, please complete the CAPTCHA (bot test) below and click "Request Access".
You may occassionally be asked to complete the CAPTCHA again, this is normal and part of our security measures. If you experiencing issues with the CAPTCHA or want to request a wider IP range, you can use the "Site Help" button found in the lower, right of this page This contact form is only for IP Access help. Please do not provide confidential information or personal data.
* I am requesting technical help. aria-label="Open site help form">
Based on current listing details, eligibility includes: Any interested party or member of the public may submit comments in response to this FDA Request for Information. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not a grant with a specific award amount, but a request for information on a proposed pilot program. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is May 29, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Orphan Products Grants Program is sponsored by U.S. Food and Drug Administration (FDA). This program awards grants to clinical investigators to support the development of safe and effective medical products (drugs, biologics, medical devices, and foods for medical purposes) for patients with rare diseases or conditions, defined as those affecting fewer than 200,000 persons in the United States. Urea cycle disorders fall under this definition. The program funds clinical trials and natural history studies.
Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) is sponsored by National Science Foundation (NSF) / National Institutes of Health (NIH) / Food and Drug Administration (FDA). This program supports interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models…